- After instituting a partial clinical hold on Aprea Therapeutics Inc's APRE myeloid malignancies program, the FDA has placed a clinical hold on Aprea's lymphoid malignancy study.
- The trial is evaluating eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies.
- The agency's concerns referred to the safety and efficacy data from the Phase 3 myelodysplastic syndromes (MDS) clinical trial.
- One chronic lymphocytic leukemia (CLL) patient is currently on study treatment receiving eprenetapopt / venetoclax / rituximab combo and has achieved complete remission (CR).
- No additional patients can be enrolled until the clinical hold is resolved.
- Price Action: APRE shares are down 12.20% at $3.60 during the premarket session on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsPenny StocksShort IdeasHealth CareFDAMoversTrading IdeasGeneralBriefsmyelodysplastic syndrome
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
